人类血液凝固因子IX年龄调节的遗传机制
S Kurachi1, Y Deyashiki, J Takeshita
1Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109-0618, USA. kkurachi@umich.edu
概括
血液凝结率随着年龄的增长而增加. 研究人员确定了两个调节因子IX基因表达的基因元素,AE5'和AE3',解释了与年龄相关的血液凝固变化.
科学领域:
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
- 衰老研究研究 衰老研究
背景情况:
- 在健康人群中,血液凝固能力自然会随着年龄的增长而增加.
- 第九因子基因表达在凝血级联中起着至关重要的作用.
- 了解与年龄相关的基因调节对于理解衰老过程中的生理变化至关重要.
研究的目的:
- 确定和描述负责人体因子IX基因表达中年龄相关变化的调控元素.
- 阐明已识别的元素在保持稳定性和随着时间的推移提高基因表达的特定作用.
主要方法:
- 在转基因小鼠中对人类因子IX基因表达的纵向分析.
- 特定的DNA调节元件 (AE5'和AE3') 的识别和功能性表征.
主要成果:
- 在因子IX基因中确定了两个重要的年龄调节元素,AE5'和AE3'.
- 位于5'上游区域的AE5'可确保基因表达稳定.
- 位于3'非翻译区域的AE3'驱动着与年龄相关的信使RNA水平的增加.
结论:
- AE5'和AE3'是共同需要的,并且足以正常调节因子IX基因表达的年龄.
- 这些元素协同作用,准确地回顾了因子IX基因表达的自然与年龄相关的增加.
- 这些发现为了解与年龄相关的血液凝结能力变化提供了分子基础.
相关概念视频
Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
General Transcription Factors
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Factors Affecting Erythropoiesis
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...


